Fig. 1 (abstract P423).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part TwoOverall Survival of Patients with Stage IIIB NSCLC, From Start of Third Cycle of ChemotherapyBack to article page